Physician profile
Stacy Tompkins
NPI 1255418265
$6,813.39
in general payments reported to CMS, 2019-2025
29 companies · $328 in 2025
The $328 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,493 · 2020: $326 · 2021: $145 · 2022: $1,445 · 2023: $1,299 · 2024: $1,777 · 2025: $328.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,215 · Education: $189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,214.85 |
| Education | $188.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,255.21 | 2019-2025 | Rinvoq, Skyrizi |
| Incyte Corporation | $629.32 | 2022-2025 | Opzelura |
| Pfizer INC. | $557.20 | 2019-2025 | |
| Janssen Biotech, INC. | $553.27 | 2019-2024 | Tremfya, Stelara, Remicade |
| Regeneron Healthcare Solutions, INC. | $521.78 | 2019-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $451.81 | 2019-2025 | |
| Lilly USA, LLC | $413.61 | 2019-2024 | Taltz, Olumiant, Zepbound |
| Sun Pharmaceutical Industries INC. | $364.59 | 2019-2024 | Winlevi, Absorica Ld |
| Leo Pharma INC. | $274.61 | 2019-2024 | Adbry |
| Genzyme Corporation | $271.43 | 2019-2025 | |
| Dermira, INC. | $188.24 | 2019-2020 | |
| Celgene Corporation | $180.05 | 2019 | |
| Arcutis Biotherapeutics, INC. | $164.02 | 2023-2024 | Zoryve |
| Amgen INC. | $147.97 | 2020-2025 | Otezla, Otezla |
| Biofrontera INC. | $116.13 | 2019-2024 | Xepi, Bf-Rhodoled, Ameluz |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $115.85 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $109.98 | 2019-2021 | |
| Almirall LLC | $90.90 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.75 | 2024 | Spevigo |
| Ucb, INC. | $61.44 | 2021-2024 | Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $58.37 | 2024-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $53.83 | 2022-2024 | Aklief, Epsolay, Oracea |
| Merck Sharp & Dohme LLC | $38.19 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $29.47 | 2021 | |
| Tactile Systems Technology INC | $22.00 | 2022 | |
| Dusa Pharmaceuticals, INC. | $21.63 | 2019 | |
| Dermavant Sciences, INC. | $20.29 | 2023 | Vtama |
| Strata Skin Sciences, INC. | $20.20 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $19.25 | 2024 | Valchlor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacy Tompkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.